Sponsors have increasingly adopted new clinical trial models, including decentralised trials and real-world data, but global regulatory harmonisation has been lacking.
While it discontinued the Phase III trial, AstraZeneca did announce two NSCLC successes with other oncology assets.
Ziresovir is said to be the first direct-acting RSV antiviral to complete a Phase III clinical trial with positive results.
The trial will enrol around 53 participants and aims to complete enrolment in 15 to 18 months.
The survey data comes shortly after the US Government announced Operation Trialblazer to boost Phase I research in the US.
AI is being adopted more in the clinical trial workflow as sponsors realise its potential for accelerating drug development.
